Inhibition of pressure induced bladder smooth muscle cell hyperplasia using CRM197

K. M. Haberstroh, Martin Kaefer, R. Bizios

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: In vivo the effects of sustained hydrostatic pressure on the bladder wall and its components are evident under physiological and pathological conditions. We previously reported that exposure of bladder smooth muscle cells to 20 and 40 cm. H2O hydrostatic pressure for as little as 1 hour resulted in the up-regulation of heparin binding epidermal growth factor messenger RNA in a time dependent fashion as well as in activation of the heparin binding epidermal growth factor growth factor gene. In our current study we investigated the use of CRM197 as an agent for blocking undesirable cellular level events, such as smooth muscle cell hyperplasia, eliminating the irreversible alterations in bladder and kidney function that result from chronic and/or severe bladder outlet obstruction. Materials and Methods: Control and experimental neonatal ovine smooth muscle cells were exposed to 0.3 pressure and 8.5 cm. H2O, respectively, for 7 days. We evaluated the mitogenic activity of the supernatant medium from bladder smooth muscle cells exposed to 8.5 cm. H2O for 5 days (conditioned medium) before and after the addition of 0.1 mg./ml. CRM197. Bladder smooth muscle cell apoptosis was also assessed after CRM197 exposure. Statistical analysis was performed using the Student t test with p 2O hydrostatic pressure for 7 days resulted in increased cell proliferation. Conditioned medium contained mitogenic activity, which was ablated after CRM197 was added. No direct toxic effect of CRM197 on bladder smooth muscle cell growth was appreciated (no apoptosis). Conclusions: We demonstrated a proliferative response of neonatal bladder smooth muscle cells after exposure to sustained hydrostatic pressure. This response was partially due to the release of heparin binding epidermal growth factor and was blocked by adding CRM197. These data support the potential use of CRM197 in drug targeted therapy for diseases involving bladder outlet obstruction.

Original languageEnglish (US)
Pages (from-to)1329-1333
Number of pages5
JournalJournal of Urology
Volume164
Issue number4
StatePublished - 2000
Externally publishedYes

Fingerprint

Smooth Muscle Myocytes
Hyperplasia
Urinary Bladder
Hydrostatic Pressure
Pressure
Epidermal Growth Factor
Urinary Bladder Neck Obstruction
Heparin
Conditioned Culture Medium
Apoptosis
Poisons
CRM197 (non-toxic variant of diphtheria toxin)
Sheep
Intercellular Signaling Peptides and Proteins
Up-Regulation
Cell Proliferation
Students
Kidney
Drug Therapy
Messenger RNA

Keywords

  • Bladder
  • Hydrostatic pressure
  • Mitogens
  • Muscle
  • Smooth

ASJC Scopus subject areas

  • Urology

Cite this

Inhibition of pressure induced bladder smooth muscle cell hyperplasia using CRM197. / Haberstroh, K. M.; Kaefer, Martin; Bizios, R.

In: Journal of Urology, Vol. 164, No. 4, 2000, p. 1329-1333.

Research output: Contribution to journalArticle

Haberstroh, K. M. ; Kaefer, Martin ; Bizios, R. / Inhibition of pressure induced bladder smooth muscle cell hyperplasia using CRM197. In: Journal of Urology. 2000 ; Vol. 164, No. 4. pp. 1329-1333.
@article{8affd23a680f4f119c22b5aff7773c8d,
title = "Inhibition of pressure induced bladder smooth muscle cell hyperplasia using CRM197",
abstract = "Purpose: In vivo the effects of sustained hydrostatic pressure on the bladder wall and its components are evident under physiological and pathological conditions. We previously reported that exposure of bladder smooth muscle cells to 20 and 40 cm. H2O hydrostatic pressure for as little as 1 hour resulted in the up-regulation of heparin binding epidermal growth factor messenger RNA in a time dependent fashion as well as in activation of the heparin binding epidermal growth factor growth factor gene. In our current study we investigated the use of CRM197 as an agent for blocking undesirable cellular level events, such as smooth muscle cell hyperplasia, eliminating the irreversible alterations in bladder and kidney function that result from chronic and/or severe bladder outlet obstruction. Materials and Methods: Control and experimental neonatal ovine smooth muscle cells were exposed to 0.3 pressure and 8.5 cm. H2O, respectively, for 7 days. We evaluated the mitogenic activity of the supernatant medium from bladder smooth muscle cells exposed to 8.5 cm. H2O for 5 days (conditioned medium) before and after the addition of 0.1 mg./ml. CRM197. Bladder smooth muscle cell apoptosis was also assessed after CRM197 exposure. Statistical analysis was performed using the Student t test with p 2O hydrostatic pressure for 7 days resulted in increased cell proliferation. Conditioned medium contained mitogenic activity, which was ablated after CRM197 was added. No direct toxic effect of CRM197 on bladder smooth muscle cell growth was appreciated (no apoptosis). Conclusions: We demonstrated a proliferative response of neonatal bladder smooth muscle cells after exposure to sustained hydrostatic pressure. This response was partially due to the release of heparin binding epidermal growth factor and was blocked by adding CRM197. These data support the potential use of CRM197 in drug targeted therapy for diseases involving bladder outlet obstruction.",
keywords = "Bladder, Hydrostatic pressure, Mitogens, Muscle, Smooth",
author = "Haberstroh, {K. M.} and Martin Kaefer and R. Bizios",
year = "2000",
language = "English (US)",
volume = "164",
pages = "1329--1333",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Inhibition of pressure induced bladder smooth muscle cell hyperplasia using CRM197

AU - Haberstroh, K. M.

AU - Kaefer, Martin

AU - Bizios, R.

PY - 2000

Y1 - 2000

N2 - Purpose: In vivo the effects of sustained hydrostatic pressure on the bladder wall and its components are evident under physiological and pathological conditions. We previously reported that exposure of bladder smooth muscle cells to 20 and 40 cm. H2O hydrostatic pressure for as little as 1 hour resulted in the up-regulation of heparin binding epidermal growth factor messenger RNA in a time dependent fashion as well as in activation of the heparin binding epidermal growth factor growth factor gene. In our current study we investigated the use of CRM197 as an agent for blocking undesirable cellular level events, such as smooth muscle cell hyperplasia, eliminating the irreversible alterations in bladder and kidney function that result from chronic and/or severe bladder outlet obstruction. Materials and Methods: Control and experimental neonatal ovine smooth muscle cells were exposed to 0.3 pressure and 8.5 cm. H2O, respectively, for 7 days. We evaluated the mitogenic activity of the supernatant medium from bladder smooth muscle cells exposed to 8.5 cm. H2O for 5 days (conditioned medium) before and after the addition of 0.1 mg./ml. CRM197. Bladder smooth muscle cell apoptosis was also assessed after CRM197 exposure. Statistical analysis was performed using the Student t test with p 2O hydrostatic pressure for 7 days resulted in increased cell proliferation. Conditioned medium contained mitogenic activity, which was ablated after CRM197 was added. No direct toxic effect of CRM197 on bladder smooth muscle cell growth was appreciated (no apoptosis). Conclusions: We demonstrated a proliferative response of neonatal bladder smooth muscle cells after exposure to sustained hydrostatic pressure. This response was partially due to the release of heparin binding epidermal growth factor and was blocked by adding CRM197. These data support the potential use of CRM197 in drug targeted therapy for diseases involving bladder outlet obstruction.

AB - Purpose: In vivo the effects of sustained hydrostatic pressure on the bladder wall and its components are evident under physiological and pathological conditions. We previously reported that exposure of bladder smooth muscle cells to 20 and 40 cm. H2O hydrostatic pressure for as little as 1 hour resulted in the up-regulation of heparin binding epidermal growth factor messenger RNA in a time dependent fashion as well as in activation of the heparin binding epidermal growth factor growth factor gene. In our current study we investigated the use of CRM197 as an agent for blocking undesirable cellular level events, such as smooth muscle cell hyperplasia, eliminating the irreversible alterations in bladder and kidney function that result from chronic and/or severe bladder outlet obstruction. Materials and Methods: Control and experimental neonatal ovine smooth muscle cells were exposed to 0.3 pressure and 8.5 cm. H2O, respectively, for 7 days. We evaluated the mitogenic activity of the supernatant medium from bladder smooth muscle cells exposed to 8.5 cm. H2O for 5 days (conditioned medium) before and after the addition of 0.1 mg./ml. CRM197. Bladder smooth muscle cell apoptosis was also assessed after CRM197 exposure. Statistical analysis was performed using the Student t test with p 2O hydrostatic pressure for 7 days resulted in increased cell proliferation. Conditioned medium contained mitogenic activity, which was ablated after CRM197 was added. No direct toxic effect of CRM197 on bladder smooth muscle cell growth was appreciated (no apoptosis). Conclusions: We demonstrated a proliferative response of neonatal bladder smooth muscle cells after exposure to sustained hydrostatic pressure. This response was partially due to the release of heparin binding epidermal growth factor and was blocked by adding CRM197. These data support the potential use of CRM197 in drug targeted therapy for diseases involving bladder outlet obstruction.

KW - Bladder

KW - Hydrostatic pressure

KW - Mitogens

KW - Muscle

KW - Smooth

UR - http://www.scopus.com/inward/record.url?scp=0033812299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033812299&partnerID=8YFLogxK

M3 - Article

VL - 164

SP - 1329

EP - 1333

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -